BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 3543275)

  • 1. The cellular composition of human lymph nodes after allogenic bone marrow transplantation: an immunohistological study.
    Dilly SA; Sloane JP; Psalti IS
    J Pathol; 1986 Nov; 150(3):213-21. PubMed ID: 3543275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular composition of the spleen after human allogeneic bone marrow transplantation.
    Dilly SA; Sloane JP
    J Pathol; 1988 Jun; 155(2):151-60. PubMed ID: 3292736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in rectal leucocytes after allogeneic bone marrow transplantation.
    Dilly SA; Sloane JP
    Clin Exp Immunol; 1987 Jan; 67(1):151-8. PubMed ID: 3304737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T lymphocyte regeneration after transplantation of T cell depleted allogeneic bone marrow.
    Janossy G; Prentice HG; Grob JP; Ivory K; Tidman N; Grundy J; Favrot M; Brenner MK; Campana D; Blacklock HA
    Clin Exp Immunol; 1986 Mar; 63(3):577-86. PubMed ID: 3011326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An immunohistological study of human hepatic graft-versus-host disease.
    Dilly SA; Sloane JP
    Clin Exp Immunol; 1985 Dec; 62(3):545-53. PubMed ID: 3910317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of cytomegalovirus infection on T lymphocytes after allogeneic bone marrow transplantation.
    Würsch AM; Gratama JW; Middeldorp JM; Nissen C; Gratwohl A; Speck B; Jansen J; D'Amaro J; The TH; De Gast GC
    Clin Exp Immunol; 1985 Nov; 62(2):278-87. PubMed ID: 3002684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
    Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
    Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological reconstitution after bone marrow transplant with Campath-1 treated bone marrow.
    Parreira A; Smith J; Hows JM; Smithers SA; Apperley J; Rombos Y; Goldman JM; Gordon-Smith EC; Catovsky D
    Clin Exp Immunol; 1987 Jan; 67(1):142-50. PubMed ID: 3304736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous superantigens in allogeneic bone marrow transplant recipients rapidly and selectively expand donor T cells which can produce IFN-gamma.
    Jones MS; Riley R; Hamilton BL; Paupe J; Perez D; Levy RB
    Bone Marrow Transplant; 1994 Nov; 14(5):725-35. PubMed ID: 7889005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
    Jabado N; Le Deist F; Cant A; De Graeff-Meeders ER; Fasth A; Morgan G; Vellodi A; Hale G; Bujan W; Thomas C; Cavazzana-Calvo M; Wijdenes J; Fischer A
    Pediatrics; 1996 Sep; 98(3 Pt 1):420-8. PubMed ID: 8784367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoreconstitution after human bone marrow transplantation.
    Zintl F; Prager J; Sauerbrey A; Metzner G; Hermann J; Fuchs D
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(3-4):519-26. PubMed ID: 2480301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation.
    Keever-Taylor CA; Passweg J; Kawanishi Y; Casper J; Flomenberg N; Baxter-Lowe LA
    Bone Marrow Transplant; 1997 May; 19(10):1001-9. PubMed ID: 9169644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One haplotype matched bone marrow grafts: an investigation using the HLA system as a marker of cellular origin.
    Jones EH; Lawler SD; Powles RL
    Dis Markers; 1988 Mar; 6(1):47-55. PubMed ID: 3293882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell phenotypic profile and colony formation during recovery from cytotoxic therapy-induced marrow aplasia.
    Ashkenazi YJ; Barth KC; Elfenbein GJ
    Cancer Res; 1985 Dec; 45(12 Pt 1):6513-8. PubMed ID: 3933827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
    Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
    Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA
    Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Sanchez J; Casaño J; Alvarez MA; Roman-Gomez J; Martin C; Martinez F; Gomez P; Serrano J; Herrera C; Torres A
    Br J Haematol; 2004 Sep; 126(5):697-703. PubMed ID: 15327522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.